Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide (1). This has only grown worse during the COVID-19 pandemic, with early estimates suggesting prevalence rates up to 25% (2). Although our understanding of depression has expanded greatly, current therapeutic treatments only work in a subpopulation of individuals (1). Clearly, more work is needed to develop effective treatments, and a necessary first step in that endeavor is to understand the neurocircuitry underlying MDD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
